Clinical Trial Update: MISurf Versus InSurE. A Comparison of Minimally Invasive Surfactant Application Techniques in Preterm Infants [Phase 2]

View source ↗

Summary

This Phase 2 trial update reports termination of the MISurf vs InSurE surfactant delivery study in preterm infants with hyaline membrane disease.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Neonatal Respiratory Distress Syndrome

Snippet

Sponsor: Hamilton Health Sciences Corporation | Conditions: Hyaline Membrane Disease | Phase 2 | Status: TERMINATED